NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









TolerogenixX GmbH

TolerogenixX GmbH

Private
HeidelbergHealthcare & Life Scienceshttps://www.tolerogenixx.com/

Last Round

Series A

Jul 6, 2023

Total Funding Raised

$12.63M

Company Overview

TolerogenixX GmbH is a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

personalized cell therapyimmune toleranceorgan transplantationtolerogenic cell therapymodified immune cellsimmunosuppression reductionkidney transplantationclinical stage biopharmacell and gene therapydonor-specific toleranceCGTex-vivo cell therapyadvanced therapy medicinal productATMPautoimmune disease therapyregenerative medicineMIC technology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

TolerogenixX GmbH Comparables

Compare TolerogenixX GmbH with similar companies based on industry and business-model similarity.

TolerogenixX GmbH comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Medeor Therapeutics
85%
Quell Therapeutics
78%
Cell4Cure AB
75%

TolerogenixX GmbH Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJul 6, 2023
SeedMay 23, 2017

TolerogenixX GmbH Investors

Notable investors and investment history

TolerogenixX GmbH investors
InvestorRounds
High-Tech GründerfondsSeries A, Seed
KalodionSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 6, 2023

    $13M round led by High-Tech Gründerfonds.

  • May 23, 2017

    Seed round led by High-Tech Gründerfonds.

TolerogenixX GmbH Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

TolerogenixX GmbH Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about TolerogenixX GmbH's valuation, stock price, and market status.

Firmographic Details

HeadquartersHeidelberg
Employee Range4
Year Founded2016
Last FundingJul 6, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.